Manufacturing

Articles

Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.

Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland

AGC Biologics has broken ground on a new multipurpose facility in Copenhagen, Denmark, that will increase capacity.

AGC Biologics Breaks Ground on New Multipurpose Facility in Denmark

Lonza plans to establish drug product manufacturing capabilities at is site in Guangzhou, China, to produce clinical trial and commercial supply in the country.

Lonza Invests in Drug Product Manufacturing Services in China

Syngene’s additions include a new microbial facility and an expanded mammalian facility.

Syngene Expands Microbial and Mammalian Manufacturing Facilities in Bengalaru

BeiGene plans to build a new campus for R&D and commercial-scale biopharmaceutical manufacturing in Hopewell, NJ.

BeiGene to Build New Manufacturing and Clinical R&D Facility in New Jersey

Emergent BioSolutions is being allowed to restart manufacturing operations for the J&J COVID-19 vaccine at its Bayview, Baltimore, Md., facility.

FDA Gives Green Light to Emergent BioSolutions to Resume COVID-19 Vaccine Manufacturing

Samsung Biologics and Kineta have entered into a strategic partnership for drug product manufacturing services and to support an IND filing of a novel antibody therapeutic. 

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy

The US federal government awarded new funding to the National Institute for Innovation in Manufacturing Biopharmaceuticals, including funding under the American Rescue Plan that will be used to advance vaccine manufacturing. 

NIIMBL Receives Federal Funding for Biopharmaceutical Manufacturing Projects

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

Sparx Therapeutics to Build Commercial Antibody Manufacturing Facility in China

The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.

Manufacturing, Biologic Drugs